1. Anisamide-conjugated hairpin antisense oligonucleotides prodrug co-delivering doxorubicin exhibited enhanced anticancer efficacy
- Author
-
Zhe Zhang, Zuyi Chen, Shuangshuang Liu, Zhenyu Xiao, Yuan Luo, Xiaochen Pan, Xuesong Feng, and Liang Xu
- Subjects
Antisense oligonucleotide ,Prodrug ,Anisamide-conjugation ,Doxorubicin ,Cellar uptake ,Anti-tumor ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Antisense oligonucleotides (ASONs)-based therapeutics offers tremendous promise for the treatment of diverse diseases. However, there is still a need to develop ASONs with enhanced stability against enzymes, improved drug delivery, and enhanced biological potency. In this study, we propose a novel anisamide (AA)-conjugated hairpin oligonucleotide prodrug loading with chemotherapeutic agent (doxorubicin, DOX) (AA-loop-ASON/DOX) for oncotherapy. Results indicated that the introduction of a hairpin conformation and AA ligand in prodrug significantly improved the stability against enzymatic hydrolysis, as well as the cellar uptake of ASONs and DOX. The incorporation of disulfide bonds could trigger mechanical opening, resulting in the release of ASON and DOX in response to the intracellular glutathione (GSH) in tumors. Moreover, the composite of DOX-loading ASONs prodrug exhibited a robust and selective inhibition of tumor cell proliferation. This paper introduces a novel design concept for nucleic acid-based therapeutics, aiming to enhance the delivery of drug and improve biological effectiveness.
- Published
- 2024
- Full Text
- View/download PDF